Oncopeptides says peptide drug conjugate crosses blood-brain barrier in glioblastoma
The Swedish company will host an October 12 webcast on interim results from its OP-701 INSULA window-of-opportunity study.
TR
By Tom Reyes · Markets Editor
Oct 9 07:30 ETSource: TradingView
The wire
- 01Oncopeptides announced positive interim data from the ongoing OP-701 (INSULA) window-of-opportunity study, saying its peptide drug conjugate platform penetrated the human blood-brain barrier in glioblastoma patients.
- 02Peptide drug conjugates reaching intracranial tumours would extend the platform beyond the company's commercialised multiple myeloma product into a hard-to-treat indication.
- 03CEO Sofia Heigis and CFO Henrik Bergentoft present details on October 12 at 08:00 CET; the data are company-reported interim results from a small early study.
From the source
Read at tradingview.comInvitation to Oncopeptides’ investor webcast following positive glioblastoma data
STOCKHOLM — October 9, 2026 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, invites investors, analysts, and media to an audiocast and telephone conference on Monday, October 12, 2026, at 08:00 CET.
